Renuka Umashanker, MD
Gastroenterology · Hamden, CTNPI 1437130309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,905 of the $197,046 with a category attached, or 85.2%. 30 manufacturers reported payments, led by Gilead at 40.4% of the total. 2025 is the largest year on record at $63,607, 2.3 times the $27,068 reported in 2019. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 701 payments — averaging $281.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$80K
- AbbVie$77K
- Madrigal Pharmaceuticals$36K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$486
- QOL Medical, LLC$393
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$167,90585%
- Travel & lodging$15,5968%
- Food & beverage$13,5457%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 228 | $79,635 |
| AbbVie(2 entities) | 261 | $76,581 |
| Madrigal Pharmaceuticals | 53 | $36,053 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $1,649 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $486 |
| QOL Medical, LLC | 16 | $393 |
| Ironwood Pharmaceuticals, Inc | 19 | $343 |
| Ardelyx, Inc. | 15 | $326 |
| Intercept Pharmaceuticals, Inc. | 15 | $284 |
| Bristol Myers Squibb | 7 | $194 |
| Novo Nordisk | 6 | $160 |
| Pfizer | 9 | $154 |
| Ipsen Biopharmaceuticals, Inc | 5 | $110 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Ferring Pharmaceuticals Inc. | 4 | $75 |
| Johnson & Johnson | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 5 | $61 |
| Braintree Laboratories, Inc. | 2 | $51 |
| Mirum Pharmaceuticals, Inc. | 2 | $48 |
| Shionogi Inc | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $41 |
| Echosens North America, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Pentax Of America, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,046 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 24 | $74,529 |
| LinzessLinaclotide | 55 | $44,677 |
| RezdiffraResmetirom | 11 | $44,601 |
| VoqueznaVonoprazan Fumarate | 42 | $32,879 |
| Dexlansoprazole DrDexlansoprazole | 94 | $29,072 |
| OzempicSemaglutide | 12 | $27,216 |
| Mesalamine | 45 | $20,182 |
| MotegrityPrucalopride Succinate | 11 | $10,840 |
| DexilantDexlansoprazole | 13 | $7,508 |
| Omeprazole | 445 | $6,955 |
| Ursodiol | 30 | $6,441 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 30 | $5,224 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 83 | $5,009 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 16 | $2,588 |
| Sucralfate | 15 | $2,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,649 | $74,52924 claims |
| AbbVieLinzess | $76,581 | $44,67755 claims |
| Madrigal PharmaceuticalsRezdiffra | $36,053 | $44,60111 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $61 | $32,87942 claims |
| Novo NordiskOzempic | $160 | $27,21612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $486 | $18,34824 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $75 | $5,22430 claims |
| Braintree Laboratories, Inc.Sutab | $51 | $2,58816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Hamden
- Paul FeuerstadtHamden$1M
- David HassHamden$173K
- Karl LangbergHamden$17K
- Dean ChangHamden$16K
- Benigno VarelaHamden$16K
- Mark TaylorHamden$13K
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.